

Lung Cancer Quality Performance Indicator Specifications

LCQI08 Radiation Treatment

2021

Citation: Te Aho o Te Kahu. 2021. *Lung Cancer Quality Performance Indicator Specifications: LCQI08 Radiation Treatment*. Wellington: Te Aho o Te Kahu.

Published in March 2021 by the Te Aho o Te Kahu
PO Box 5013, Wellington 6140, New Zealand

ISBN 978-1-99-002989-9 (online)
HP 7604



This document is available at teaho.govt.nz



This work is licensed under the Creative Commons Attribution 4.0 International licence. In essence, you are free to: share ie, copy and redistribute the material in any medium or format; adapt ie, remix, transform and build upon the material. You must give appropriate credit, provide a link to the licence and indicate if changes were made.

Contents

Introduction	1
Sources of data for indicator	1
LCQI08 Radiation treatment	2
Measure items	2
Case eligibility criteria (denominator)	3
Numerator criteria	4
Chemotherapy drug codes and names	5

Introduction

This information is provided to make it easier for analysts to replicate our calculations. For each measure we have provided supporting information, a table and a flow diagram.

This document provides specifications for the following measure.

Measure	Measure abbreviation	Measure type
i) Proportion of people with lung cancer receiving radiation treatment, by intent and type of lung cancer (NSCLC/SCLC)	Radiation	Quality improvement
ii) Proportion of people with primary lung cancer receiving stereotactic ablative radiation therapy (SABR), intent and type of lung cancer (NSCLC/SCLC)	SABR	Quality improvement
iii) Proportion of people with lung cancer receiving concurrent chemoradiation, by intent and type of lung cancer (NSCLC/SCLC)	Chemoradiation	Quality improvement

Sources of data for indicator

- New Zealand Cancer Registry (NZCR) – a population-based register of all primary malignant diseases diagnosed in New Zealand, excluding squamous and basal cell skin cancers
- Radiation Oncology Collection (ROC) – a collection of radiation oncology treatment data, including both public and private providers.
- Pharmaceutical Collection (PHARMS) – a data warehouse that supports the management of pharmaceutical subsidies, and contains claim and payment information from pharmacists for subsidised dispensings
- National Non-Admitted Patients Collection (NNPAC) – includes event-based purchase units that relate to medical and surgical outpatient events and emergency department events

More information on these data sources can be found on the Ministry of Health's website: www.health.govt.nz.

LCQI08

Radiation treatment

- i) Proportion of people with lung cancer receiving radiation treatment, by, intent and type of lung cancer (NSCLC/SCLC).
- ii) Proportion of people with primary lung cancer receiving stereotactic ablative radiation therapy (SABR), by intent and type of lung cancer (NSCLC/SCLC).
- iii) Proportion of people with lung cancer receiving concurrent chemoradiation, by intent and type of lung cancer (NSCLC/SCLC).

Measure type: quality improvement

Measure items

Dataset	Data item	Description
NZCR	NHI	Patient identifier
NZCR	Cancer event ID	Cancer registration identifier
NZCR	Date of initial diagnosis	Date person first diagnosed with lung cancer
NZCR	Diagnosis year	Calendar year of first diagnosis
NZCR	Site	Primary organ of origin of the cancer (ICD-10-AM 8 th Edition code)
NZCR	Morphology code	4-digit code (ICD-O-3) for microscopic or cellular anatomy of the cancer
NZCR	Basis	Basis of diagnosis
NZCR	DHB of domicile	DHB code for domicile of patient at diagnosis
NZCR	DHB	DHB name based on domicile of patient at diagnosis
NZCR	Age at diagnosis	Age of patient at diagnosis in years
NZCR	Prioritised ethnicity	Ethnic group derived from patient's ethnicity
NZCR	Sex	Sex of patient
NZCR	Deprivation quintile	NZDep2013 index of social deprivation quintile based on patient's domicile
NZCR	Date of death	Date patient died
NZCR	TNM_T	Stage at diagnosis – tumour
NZCR	TNM_N	Stage at diagnosis – node
NZCR	TNM_M	Stage at diagnosis – metastases
NZCR	Behaviour code	Neoplastic behaviour of the cancer

Dataset	Data item	Description
NZCR	Multiple tumour flags	Person diagnosed with more than one tumour
NZCR	Registration status code	Status of registration processing
ROC	Start date	Date of treatment start
ROC	End date	Date of treatment end
ROC	Treatment occurrence	Treatment occurrence
ROC	Intent of treatment	Intent of treatment indicator
ROC	Fractionation	Planned fractions
ROC	Dose	Dosage used
ROC	Facility	Facility of service
PHARMS	Date of dispensing	Date of dispensing of chemotherapy drugs
PHARMS	Chemical ID	Identifier for drug
PHARMS	Chemical name	Name of chemotherapy drug

Case eligibility criteria (denominator)

Diagram reference	Assessment	Item	Codes
1	First or only diagnosis of malignant neoplasm	Primary site	First diagnosis of lung cancer (trachea C33 or bronchus C34)
2	Exclude manually censored case	Exclusion	Registration codes not R_C (registered complete) or R_R (registered) No incident cancer (exclude people with multiple tumour flags = yes) People diagnosed following death certificate only (basis = 0) People domiciled outside of New Zealand (DHB_code = 999) Cancer morphologies of melanoma, sarcoma and other unusual morphologies (codes 8333, 8720, 8772, 8800, 8801, 8803, 8805, 8815, 8890, 9040, 9041, 9133)
3	Diagnosis date	Date of initial diagnosis	2015–18
4	Male or female	Sex	M or F
5	Adult patient 18 years and older at diagnosis	Age at diagnosis	18 years and older
6	Invasive tumours	Behaviour code	3

Diagram reference	Assessment	Item	Codes
7	Cancer type	Morphology code	Non-small cell lung cancer: - All morphology codes except codes for SCLC (8041, 8042, 8043, 8044 and 8054) and other/unspecified lung cancers (8000, 8010, 8020, 8240, 8244, 8249) Small cell lung cancer: - Morphology codes 8041, 8042, 8043, 8044 and 8054

Numerator criteria

Diagram reference	Assessment	Item	Codes
8i	Proportion of people with lung cancer receiving radiation treatment	Radiotherapy	From ROC dataset, include patients with: - treatment_occurrence = "First Treatment" - clinical_code_icd10_am8 like ("C33%", "C34%") - Treatment start date between -30 and 275 days from diagnosis date
8ii	Proportion of people with lung cancer receiving stereotactic ablative radiotherapy	SABR	From ROC dataset, include patients with: - treatment_occurrence = "First Treatment" - clinical_code_icd10_am8 like ("C33%", "C34%") - Treatment intent = 1 (curative) - Dose between 48 GY and 60 GY - Fractionation between 3# and 8# - Treatment start date between -30 and 275 days from diagnosis date
8iii	Proportion of people with lung cancer receiving concurrent chemoradiation	Chemoradiation	From ROC dataset, include patients with: - treatment_occurrence = "First Treatment" - clinical_code_icd10_am8 like ("C33%", "C34%") - Treatment start date between -30 and 275 days from diagnosis date AND From PHARMS dataset, include patients with: - Drugs with chemical ID 3826, 3825, 2433, 3847, 3811, 3815, 3834, 3842, 3816, 4088, 3966, 3916, 1369, 3813, 2319, 2320 AND - PHARMS date of dispensing between ROC start date and ROC end date

Chemotherapy drug codes and names

Chemical ID	Chemical name
3826	Cisplatin
3825	Carboplatin
2433	Etoposide
3847	Etoposide phosphate
3811	Irinotecan hydrochloride
3815	Paclitaxel
3834	Docetaxel
3842	Gemcitabine hydrochloride
3816	Vinorelbine
4088	Pemetrexed
3966	Gefitinib
3916	Erlotinib hydrochloride
1369	Cyclophosphamide
3813	Doxorubicin
2319	Vinblastine sulphate
2320	Vincristine sulphate

